Spero Therapeutics Inc
SPRO2.420USD
+0.120+5.22%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
136.27MCap. mercado
PérdidaP/E TTM
Más Datos de Spero Therapeutics Inc Compañía
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Información de Spero Therapeutics Inc
Símbolo de cotizaciónSPRO
Nombre de la empresaSpero Therapeutics Inc
Fecha de salida a bolsaNov 02, 2017
Director ejecutivoRajavelu (Esther)
Número de empleados32
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 02
Dirección675 Massachusetts Ave Ste 14
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139-3309
Teléfono18572421600
Sitio Webhttps://sperotherapeutics.com/
Símbolo de cotizaciónSPRO
Fecha de salida a bolsaNov 02, 2017
Director ejecutivoRajavelu (Esther)
Ejecutivos de Spero Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-40270.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1695.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+20000.00%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
188.41K
-40270.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
145.31K
-1695.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Por negocioUSD
Nombre
Ganancia
Proporción
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
5.44M
100.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
Otro
70.37%
Accionistas
Accionistas
Proporción
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
Otro
70.37%
Tipos de accionistas
Accionistas
Proporción
Corporation
20.51%
Hedge Fund
6.27%
Investment Advisor
5.88%
Individual Investor
2.87%
Investment Advisor/Hedge Fund
2.52%
Venture Capital
1.64%
Research Firm
0.20%
Bank and Trust
0.02%
Otro
60.09%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
108
9.24M
16.40%
-3.05M
2025Q3
106
9.05M
16.08%
-5.89M
2025Q2
114
26.06M
46.61%
-2.84M
2025Q1
116
27.38M
49.07%
-1.56M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
GSK plc
9.19M
16.31%
--
--
Mar 27, 2025
Pfizer Inc
2.36M
4.19%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.99M
3.53%
+39.47K
+2.02%
Sep 30, 2025
Anson Funds Management LP.
1.60M
2.85%
-11.90K
-0.74%
Sep 30, 2025
Renaissance Technologies LLC
1.45M
2.58%
+620.60K
+74.58%
Sep 30, 2025
Alphabet, Inc.
889.98K
1.58%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
527.48K
0.94%
+16.78K
+3.29%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
433.55K
0.77%
--
--
Sep 30, 2025
Rajavelu (Esther)
188.41K
0.33%
-40.27K
-17.61%
Nov 07, 2025
Mahadevia (Ankit)
364.22K
0.65%
-6.57K
-1.77%
Aug 28, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.63%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.63%
Avantis US Small Cap Equity ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
